Page 1 Extracted Terms:
**Key heart‑disease–related terms extracted**

- Lower extremity peripheral artery disease  
- Peripheral artery disease  
- Asymptomatic peripheral artery disease  
- Chronic symptomatic peripheral artery disease  
- Chronic limb‑threatening ischemia  
- Acute limb ischemia  
- Vascular disease  
- Cardiovascular  
- Endovascular surgery  
- Interventional radiology  
- Angiography  
- Vascular surgery  
- Vascular nursing  
- Clinical practice guidelines  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- AACVPR (American Association of Cardiovascular and Pulmonary Rehabilitation)  
- APMA (American Podiatric Medical Association)  
- ABC (Association of Black Cardiologists)  
- SCAI (Society for Cardiovascular Angiography and Interventions)  
- SVM (Society for Vascular Medicine)  
- SVN (Society for Vascular Nursing)  
- SVS (Society for Vascular Surgery)  
- SIR (Society of Interventional Radiology)  
- VESS (Vascular & Endovascular Surgery Society)  
- Guideline  
- Evidence  
- Literature review  
- PubMed  
- EMBASE  
- Cochrane Library  
- CINHL Complete  

These terms capture the primary clinical, procedural, and organizational concepts related to heart and vascular disease present in the provided guideline text.

Page 2 Extracted Terms:
**Key terms related to heart disease extracted from the guideline text**

- Atherosclerosis  
- Antiplatelet therapy  
- Anticoagulation therapy  
- Antithrombotic therapy  
- Lipid‑lowering therapy  
- Antihypertensive therapy  
- Statin therapy  
- Cardiovascular risk reduction  
- Diabetes management (as a key cardiovascular risk factor)  
- Smoking cessation  
- Acute limb ischemia (a manifestation of systemic arterial occlusion)  
- Chronic limb‑threatening ischemia (CLTI, indicating severe systemic atherosclerosis)  
- Peripheral arterial disease (PAD) – the overarching vascular disorder linked to coronary disease  
- Ischemia (general term encompassing myocardial, limb, and other tissue ischemia)  
- Revascularization (both endovascular and open surgical)  
- Endovascular therapy  
- Bypass grafting / vascular surgery  
- Stenting  
- Thrombolysis  
- Blood pressure lowering  
- Cardiovascular risk amplifiers (e.g., older age, sex, comorbidities)  

These terms capture the core cardiovascular components addressed in the guideline, even though the primary focus is on peripheral vascular disease.

Page 3 Extracted Terms:
- Peripheral artery disease (PAD)  
- Cardiovascular disease (CVD)  
- Myocardial infarction  
- Stroke  
- Ankle‑brachial index  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Lipid‑lowering therapy  
- High‑intensity statin  
- Antihypertensive therapy  
- Diabetes management  
- Smoking cessation  
- Rivaroxaban  
- Aspirin  
- Structured exercise therapy  
- Endovascular revascularization  
- Surgical revascularization  
- Hybrid revascularization  
- Limb loss (prevention)  
- Foot care (preventive and advanced)  
- Wound‑healing therapies  
- Foot surgery  
- Multispecialty care team  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)

Page 4 Extracted Terms:
**Key Heart‑Disease Related Terms Extracted**

- Peripheral Artery Disease (PAD)  
- Cardiovascular disease  
- Heart disease  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- AHA/ACC Joint Committee on Clinical Practice Guidelines  
- Guideline‑directed management and therapy (GDMT)  
- Clinical evaluation  
- Diagnostic testing  
- Pharmacological treatments  
- Procedural treatments  
- Drug treatment regimens  
- Devices (cardiovascular devices)  
- Benefit‑risk assessment  
- Evidence‑based methodology  
- Randomized controlled trials (RCTs)  
- Non‑randomized comparative studies  
- Cohort studies  
- Registries  
- Systematic reviews  
- Evidence review committee  
- Patient engagement  
- Comorbidities  
- Cost–value considerations  
- Clinical practice settings  
- Modularity in guideline presentation (knowledge chunk format)  
- Peer review  
- Regulatory compliance (US approval status)

Page 5 Extracted Terms:
**Key terms related to heart disease extracted from the guideline text**

- Cardiovascular disease (CVD)  
- Peripheral artery disease (PAD)  
- Atherosclerotic disease  
- Thrombotic disease  
- Lower‑extremity arteries  
- Angioplasty  
- Bypass grafting / open bypass surgery  
- Stenting  
- Thrombolysis  
- Statin therapy  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Lipid‑lowering therapy  
- Blood‑pressure‑lowering therapy  
- Diabetes (as a cardiovascular risk factor)  
- Ankle‑brachial index (diagnostic test)  
- Endovascular therapy  
- Hybrid approach (combining endovascular and open methods)  
- Exercise rehabilitation / exercise therapy / exercise training (cardiovascular rehab)  
- Smoking cessation (cardiovascular risk modification)  
- Diagnostic testing (imaging, functional testing)  
- Clinical practice guidelines (ACC, AHA, etc.)

Page 6 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Aortoiliac arterial segment  
- Femoropopliteal arterial segment  
- Infrapopliteal arterial segment  
- Vasculitis (as a cause of lower‑extremity arterial disease)  
- Fibromuscular dysplasia  
- Cystic adventitial disease  
- Perioperative cardiovascular evaluation and management  
- Dual antiplatelet therapy in coronary artery disease  
- Coronary artery disease (CAD)  
- High blood pressure / hypertension in adults  
- Blood cholesterol management  
- Stroke prevention in patients with prior stroke or transient ischemic attack  
- Chronic coronary disease management  
- Influenza vaccination as secondary prevention for cardiovascular disease  
- Cardiovascular disease (CVD) in general  
- Ankle‑brachial index measurement and interpretation  
- Aorto‑iliac arterial intervention (appropriate use)  
- Lower extremity threatened limb classification system  
- Atherosclerotic occlusive disease of the lower extremities (asymptomatic disease and claudication)  
- Claudication (intermittent claudication)  
- Diabetes type 2 – prevention of cardiovascular disease  
- Tobacco cessation treatment for cardiovascular risk reduction  
- Exercise programs for patients with PAD  
- Chronic limb‑threatening ischemia (CLTI) management  
- Critical limb ischemia (CLI) perfusion assessment  
- Peripheral artery intervention (endovascular)  
- Device selection in aorto‑iliac arterial interventions  
- Lower‑extremity amputations – reduction strategies  
- Telehealth in cardiovascular disease management  
- Diabetes management – standards of care  
- Endovascular specialist competencies for CLTI care  
- Health disparities in peripheral artery disease  
- Peripheral artery disease quality‑of‑care improvement and patient‑reported outcomes  
- Intermittent claudication management  
- Limb‑ischaemia evaluation and device deployment  
- Cardiovascular rehabilitation (ACVPR, AHA)   
- Cardiovascular and pulmonary rehabilitation (AACVPR)  
- Cardiovascular disease prevention strategies (e.g., lifestyle, pharmacologic)

Page 7 Extracted Terms:
- MACE (major adverse cardiovascular events)
- MI (myocardial infarction)
- Acute coronary syndrome (including acute MI, unstable angina)
- Stroke
- Heart failure
- Death (all‑cause or cardiovascular)
- Rehospitalization for cardiovascular causes
- Cardiovascular (as an endpoint or cause)

Page 8 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower Extremity Peripheral Artery Disease  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- AACVPR (American Association of Cardiovascular and Pulmonary Rehabilitation)  
- APMA (American Pulmonary & Medical Association)  
- ABC (American Board of Cardiology)  
- SCAI (Society for Cardiovascular Angiography & Interventions)  
- SVM (Society of Vascular Medicine)  
- SVN (Society for Vascular Nursing)  
- SVS (Society of Vascular Surgery)  
- SIR (Society of Interventional Radiology)  
- VESS (Venous and Vascular Surgery Society)  
- Management of Lower Extremity PAD  
- Class of Recommendation (COR)  
- Level of Evidence (LOE)  
- Clinical Trials  
- Interventions  
- Treatments  
- Diagnostic Testing  
- Patient Care (in the context of cardiovascular practice)

Page 9 Extracted Terms:
- Peripheral Artery Disease  
- Coronary Artery Disease  
- Cardiovascular Disease  
- Myocardial Infarction  
- Major Adverse Cardiovascular Events  
- Angiotensin‑converting Enzyme  
- Angiotensin‑converting Enzyme Inhibitor  
- Low‑Density Lipoprotein Cholesterol  
- Guideline‑Directed Medical Therapy  
- Systolic Blood Pressure  
- 6‑Minute Walk Test  
- Ankle‑Brachial Index  
- Computed Tomography Angiography  
- Magnetic Resonance Angiography  

(Note: Terms directly related to heart disease are highlighted, with related diagnostic and therapeutic concepts included.)

Page 10 Extracted Terms:
- Peripheral arterial disease (PAD)  
- Asymptomatic PAD  
- Claudication  
- Chronic symptomatic PAD  
- Chronic limb‑threatening ischemia (CLTI)  
- Acute limb ischemia (ALI)  
- Major adverse cardiovascular events (MACE)  
- Mortality  
- Atrial fibrillation  
- Revascularization  
- Fontaine classification  
- Rutherford classification  
- WIfI classification (Wound, Ischemia, Foot Infection)  
- Ischemic rest pain  

---

Page 11 Extracted Terms:
**Key terms related to heart disease**

- Peripheral Artery Disease (PAD)  
- Atherosclerotic Vascular Disease  
- Cardiovascular Risk Factors  
- Atherosclerosis  
- Coronary Artery Disease (CAD)  
- Carotid Artery Disease  
- Subclavian Artery Disease  
- Renal Artery Stenosis  
- Mesenteric Artery Stenosis  
- Abdominal Aortic Aneurysm (AAA)  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Claudication  
- Walking Impairment  
- Ankle‑Brachial Index (ABI)  
- Low/Reduced ABI  
- Lower Extremity Pulse Assessment (Femoral, Popliteal, Dorsalis Pedis, Posterior Tibial)  
- Pulse Deficits (absent, diminished, normal, bounding)  
- Vascular Bruit (epigastric, periumbilical, groin)  
- Foot Inspection & Foot Care for PAD  
- Non‑healing Lower Extremity Wound  
- Lower Extremity Gangrene  
- Peripheral Neuropathy (in patients with diabetes)  
- Erectile Dysfunction (as a PAD risk marker)  

These terms capture the cardiovascular disease concepts, risk factors, diagnostic measures, and clinical features discussed in the guideline.

Page 12 Extracted Terms:
**Key terms related to heart (cardiovascular) disease in the guideline text**

- Peripheral arterial disease (PAD)  
- Ankle‑brachial index (ABI)  
- Resting ABI  
- Exercise treadmill ABI  
- Abnormal ABI (≤ 0.90)  
- Borderline ABI (0.91–0.99)  
- Normal ABI (1.00–1.40)  
- Noncompressible ABI (> 1.40)  
- Toe‑brachial index (TBI)  
- Toe pressure  
- Transcutaneous oxygen pressure (TcPO₂)  
- Skin perfusion pressure (SPP)  
- Segmental leg pressures  
- Doppler waveforms  
- Ankle pulse volume recordings (PVR)  
- Angiography (invasive imaging)  
- Revascularization  
- Chronic limb‑threatening ischemia (CLTI)  
- Chronic symptomatic PAD  
- Exertional (claudication) pain  
- Rest pain  
- Leg ischemia  
- Risk factors for PAD (e.g., diabetes, smoking, hyperlipidemia)  
- Screening for PAD  
- Diagnostic testing for PAD  
- Clinical guideline statement  
- Evidence‑based recommendation  
- Cardiovascular disease (general term encompassing PAD)  
- Atherosclerosis (underlying pathology)  
- Ischemia (limb and systemic)  
- Peripheral vascular disease (broader term)  

These terms capture the cardiovascular/heart‑related concepts embedded in the PAD guideline narrative.

Page 13 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb-Threatening Ischemia (CLTI)  
- Critical Limb Ischemia (CLI)  
- Acute Limb Ischemia (ALI)  
- Ankle‑Brachial Index (ABI)  
- Toe‑Brachial Index (TBI)  
- Toe pressure  
- Transcutaneous partial pressure of oxygen (TcPO₂)  
- Skin perfusion pressure (SPP)  
- Doppler waveforms (continuous‑wave Doppler)  
- Plethysmographic pulse volume recording (PVR)  
- Segmental pressures  
- Leg pressure monitoring  
- Noncompressible vessels  
- Diabetes mellitus (as a modifier of PAD severity)  
- Chronic kidney disease (CKD)  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Atherosclerosis  
- Coronary artery disease (implied in GDMT)  
- Cardiac monitoring  
- Coronary calcium computed tomography (CT)  
- Abdominal aortic aneurysm (AAA) screening  
- Structured exercise programs for PAD  
- Guideline‑directed medical therapy (GDMT) for PAD  
- Vascular screening programs  
- Symptom‑free (asymptomatic) PAD  
- Functional status decline in PAD  
- Vascular laboratory assessment  
- Office‑based ABI measurement  
- Perfusion imaging techniques

(These terms capture the core heart‑and‑vascular‑related concepts presented in the guideline excerpt.)

Page 14 Extracted Terms:
- Ankle‑Brachial Index (ABI)  
- Toe‑Brachial Index (TBI)  
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Computed Tomography Angiography (CTA)  
- Magnetic Resonance Angiography (MRA)  
- Guideline‑Directed Management and Therapy (GDMT)  
- Pulse Volume Recording (PVR)  
- Skin Perfusion Pressure (SPP)  
- Transcutaneous Oxygen Pressure (TcPO₂)  
- Exercise Treadmill ABI  
- Doppler Device  
- Blood Pressure Cuff  
- Digital Arteries  
- Diabetic Neuropathy (implied comorbidity)  
- Chronic Kidney Disease (CKD, implied comorbidity)

Page 15 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Ankle‑Brachial Index (ABI)  
- Toe pressure / Toe‑Brachial Index (TBI)  
- Exercise ABI testing  
- Treadmill exercise ABI  
- Walking performance metrics (time to onset of symptoms, maximal walking time)  
- Post‑exercise ABI  
- Medical therapy (for PAD)  
- Structured exercise therapy (for PAD)  
- Revascularization (for PAD)  
- Randomized Controlled Trials (RCTs) in PAD therapy evaluation  
- Segmental limb pressure measurements  
- Peripheral Vascular Resistance (PVR)  
- Doppler waveforms (lower extremity arterial)  
- Aortoiliac arterial disease  
- Femoropopliteal arterial disease  
- Infrapopliteal arterial disease  
- Imaging for PAD (angiography, duplex ultrasound, etc.)  
- Lower‑extremity arterial waveform nomenclature  
- Vascular laboratory setting  
- Blood pressure gradients between cuffs (leg to ankle)  
- Peripheral vascular disease (general term)  
- Atherosclerotic cardiovascular disease (broader context)  
- American Heart Association (organizational reference)  
- American College of Cardiology Foundation (organizational reference)

Page 16 Extracted Terms:
- Peripheral Arterial Disease (PAD)  
- Critical Limb Ischemia (CLTI)  
- Ankle‑Brachial Index (ABI)  
- Toe‑Brachial Index (TBI)  
- Skin Perfusion Pressure (SPP)  
- Transcutaneous Oxygen Tension (TcPO₂)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Duplex ultrasound  
- Computed Tomography Angiography (CTA)  
- Magnetic Resonance Angiography (MRA)  
- Catheter angiography  
- Claudication  
- Ischemia  
- Amputation  
- Wound healing  
- Perfusion assessment  
- Revascularization strategy  
- Vascular access  
- Contrast media  
- Radiation exposure  
- Laser Doppler flowmetry  
- Laser speckle imaging  
- Pedal acceleration time  
- Spatial frequency domain imaging  
- Toe pressures  
- Continuous‑wave Doppler waveform  
- Photoplethysmographic waveform  
- Abnormal ABI/TBI values  
- Major amputation  
- Non‑healing lower‑extremity wounds  
- Structural exercise (as part of GDMT)  
- Anatomic assessment of disease severity  
- Vascular imaging modalities  
- Diagnostic imaging for PAD  
- Ankle‑brachial index assessment  
- Functional limitation of claudication  
- Revascularization planning  
- Clinical suspicion of PAD  
- Unconclusive ABI and physiological testing.

Page 17 Extracted Terms:
- Cardiovascular  
- Major adverse cardiovascular events (MACE)  
- Major adverse limb events (MALE)  
- Revascularization  
- Guideline‑directed medical therapy (GDMT)  
- Catheter angiography  
- Computed tomography angiography (CTA)  
- Magnetic resonance angiography (MRA)

Page 18 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Peripheral artery disease (PAD)  
- Major adverse cardiovascular events (MACE)  
- Major adverse limb events (MALE)  
- Chronic limb‑threatening ischemia (CLTI)  
- Chronic kidney disease (CKD)  
- End‑stage kidney disease (ESKD)  
- Diabetes mellitus  
- Smoking (current/ongoing smoking)  
- Hypertension  
- Polyvascular disease  
- Atherosclerosis (atherosclerotic disease)  
- Inflammation  
- Oxidative stress  
- Microvascular disease  
- Retinopathy  
- Neuropathy  
- Nephropathy  
- Guideline‑directed medical therapy (GDMT)  
- Antihypertensive therapy  

Page 19 Extracted Terms:
Peripheral Artery Disease (PAD)  
Myocardial Infarction (MI)  
Coronary Artery Disease (CAD)  
Cardiovascular Death  
Major Adverse Cardiac Events (MACE)  
Major Adverse Limb Events (MALE)  
Critical Limb Ischemia (CLTI/CLI)  
Endovascular Revascularization  
Lower‑Extremity Bypass Revascularization  
Polyvascular Disease  
Microvascular Disease  
Chronic Kidney Disease (CKD)  
End‑Stage Kidney Disease (ESKD)  
Diabetes Mellitus  
Smoking/Tobacco Use  
Atherosclerosis  
Ischemic Stroke  
Vascular Events (general)

Page 20 Extracted Terms:
**Key heart‑disease‑related terms extracted from the guideline text**

- Peripheral Artery Disease (PAD)  
- Myocardial Infarction (MI)  
- Stroke  
- Polyvascular disease  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Coronary Artery Disease (CAD)  
- Ankle‑Brachial Index (ABI)  
- Acute Limb Ischemia (ALI)  
- Chronic Kidney Disease (CKD)  
- End‑Stage Renal Disease (ESRD / ESKD)  
- Diabetes mellitus  
- Smoking (tobacco use)  
- Depression (ICD‑9/ICD codes)  
- Geriatric Depression Scale (GDS) – GDS ≥ 6  
- Patient Health Questionnaire – PHQ‑9 / PHQ‑8  
- Stress, Anxiety, and depressive symptoms  
- Social determinants of health (racial/ethnic disparities, socioeconomic status, rural residence)  
- Structural racism / chronic stress (“weathering”)  
- Health disparities in diagnosis, treatment, and outcomes  
- Risk‑amplifying comorbidities  
- Medical therapy: Guideline‑Directed Medical Therapy (GDMT)  
- Longitudinal follow‑up for PAD  
- Vascular Outcomes Study of ASA (VOYAGER PAD)  
- COMPASS study (cardiovascular outcomes for people using anticoagulation strategies)  
- EUCLID trial (examining ticagrelor in PAD)  
- Hazard Ratio (HR)  
- Odds Ratio (OR)  
- International Classification of Diseases (ICD)  

These terms capture the primary cardiovascular conditions, outcomes, risk factors, comorbidities, and key studies/metrics discussed within the clinical guideline text.

Page 21 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Cardiovascular Disease (CVD)  
- Major Adverse Limb Events (MALE)  
- Critical Limb‑Threatening Ischemia (CLTI)  
- Major Limb Amputation (MLA)  
- Major Adverse Cardiovascular Events (MACE)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Antiplatelet therapy  
- Statin therapy  
- Supervised exercise therapy  
- Revascularization  
- Systemic hypertension  
- Diabetes mellitus  
- Chronic Kidney Disease (CKD)  
- Stroke  
- Health disparities  
- Uninterrupted health insurance coverage  
- Tobacco product regulation  
- Clinical decision support for PAD care  
- Quality measures for PAD care  
- Policy recommendations for PAD  
- Physical exam of pulses  
- Functional decline  
- Limb‑salvage procedures

Page 22 Extracted Terms:
**Key heart‑disease–related terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Critical Limb Ischemia (CLTI)  
- Ankle‑Brachial Index (ABI)  
- Major Adverse Cardiac Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Revascularization  
  - Endovascular revascularization  
  - Surgical revascularization  
- Amputation (above‑knee, below‑knee)  
- Geriatric syndromes  
  - Frailty  
  - Sarcopenia  
  - Malnutrition  
  - Mobility impairment  
- Racial and ethnic disparities (Hispanic, Black, White, American Indian)  
- Socioeconomic status (income, education, Distressed Communities Index)  
- Geographic disparities (urban vs rural, geographic isolation, clinician shortages)  
- Atherosclerotic cardiovascular disease (CVD)  
- Comorbidities (e.g., smoking, diabetes)  

These terms capture the core clinical concepts, risk factors, interventions, and demographic factors relevant to heart disease discussion in the supplied text.

Page 23 Extracted Terms:
Peripheral artery disease (PAD)  
Chronic limb‑threatening ischemia (CLTI)  
Major adverse cardiovascular events (MACE)  
Major adverse limb events (MALE)  
Guideline‑directed medical therapy (GDMT)  
Angiotensin‑converting enzyme (ACE) inhibitor  
Angiotensin‑receptor blocker (ARB)  
Statin therapy  
Antiplatelet therapy  
Quality of life (QOL)  
Revascularization (endovascular, surgical, infrainguinal bypass)  
Amputation  
30‑day mortality  
2‑year survival  
5‑year survival  
5‑year amputation‑free survival  
Clinical frailty scale  
Modified frailty index  
Risk Analysis Index  
Geriatric Nutritional Risk Index (GNRI)  
Polypharmacy  
Frailty  
Sarcopenia  
Malnutrition  
Mobility impairment  
Functional status  
Life‑space mobility  
Multimorbidity  
Predicted survival  
Invasive treatment decisions (revascularization, amputation)

Page 24 Extracted Terms:
**Key Heart‑Disease–Related Terms**

1. Peripheral Artery Disease (PAD)  
2. Revascularization  
3. Endovascular revascularization  
4. Surgical revascularization  
5. Hybrid revascularization  
6. Major Adverse Limb Events (MALE)  
7. Major Adverse Cardiac Events (MACE)  
8. Myocardial Infarction (MI)  
9. Stroke (ischemic)  
10. Antiplatelet therapy  
11. Aspirin  
12. Clopidogrel  
13. Rivaroxaban (low‑dose)  
14. Low‑dose aspirin (aspirin + rivaroxaban)  
15. Dual antiplatelet therapy (DAPT)  
16. P2Y12 antagonist  
17. Vorapaxar  
18. Full‑intensity oral anticoagulation  
19. Atrial fibrillation (AF)  
20. Clinical Atherosclerosis (i.e., CAD, cerebrovascular disease)  
21. GMDT (Guideline‑Directed Medical Therapy) for PAD  
22. Foot care / preventive foot care  
23. Ulceration / Critical Limb‑Threatening Ischemia (CLTI)  
24. Quality of Life (QOL)  
25. Bleeding risk (major bleeding)  
26. Cardiovascular and limb events  
27. Residual cardiovascular risk  
28. Prothesis graft (surgical context)

These terms capture the central concepts, interventions, outcomes, and related conditions discussed in the guideline excerpt.

Page 25 Extracted Terms:
Peripheral Artery Disease (PAD)  
Atherosclerosis  
Atrial fibrillation  
Coronary artery disease (CAD)  
Carotid disease  
Ankle‑brachial index (ABI)  
Endovascular revascularization  
Surgical revascularization  
Percutaneous coronary intervention (PCI)  
Drug‑eluting stents (DES)  
Drug‑coated balloons (DCB)  
Paclitaxel‑coated devices  
Antiplatelet therapy  
Antithrombotic therapy  
Dual antiplatelet therapy (DAPT)  
Single antiplatelet therapy (SAPT)  
Triple therapy (full‑intensity anticoagulation + DAPT)  
Low‑dose rivaroxaban  
Low‑dose aspirin  
Rivaroxaban (full‑dose)  
Aspirin (acetylsalicylic acid)  
Clopidogrel (P2Y12 inhibitor)  
Ticagrelor (P2Y12 inhibitor)  
P2Y12 receptor antagonists  
Major Adverse Cardiac Events (MACE)  
Major Adverse Limb Events (MALE)  
Acute limb ischemia (ALI)  
Major bleeding  
Intracranial hemorrhage  
Intra‑cranial tumor / vascular abnormality  
Gastrointestinal bleeding  
VOYAGER PAD trial  
COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies)  
CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events)  
EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease)  

These terms encapsulate the principal concepts and therapeutic strategies related to heart disease addressed in the provided guideline excerpt.

Page 26 Extracted Terms:
- Peripheral artery disease (PAD)  
- Antiplatelet therapy  
- Aspirin  
- Dual antiplatelet therapy (DAPT)  
- Single antiplatelet therapy (SAPT)  
- Oral anticoagulation  
- Atrial fibrillation (Afib)  
- Venous thromboembolism (VTE)  
- Chronic limb‑threatening ischemia (CLTI)  
- Major adverse cardiovascular events (MACE)  
- Major adverse limb events (MALE)  
- Ankle‑brachial index (ABI)  
- Toe‑brachial index (TBI)  
- Percutaneous coronary intervention (PCI)  
- Endovascular revascularization  
- Symptomatic vs. asymptomatic PAD  
- Aspirin for Asymptomatic Atherosclerosis (AAA) trial  
- Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial  
- Critical Leg Ischemia Prevention (CLIPS) trial  

These terms capture the key cardiovascular and heart‑related concepts discussed in the guideline excerpt.

Page 27 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Coronary Artery Disease (CAD)  
- Myocardial Infarction (MI)  
- Major Adverse Cardiac Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Antiplatelet therapy  
- Dual antiplatelet therapy  
- Aspirin  
- Clopidogrel  
- Ticagrelor  
- Vorapaxar (thrombin receptor antagonist)  
- Warfarin  
- Rivaroxaban  
- Low‑dose aspirin  
- High‑intensity statin therapy  
- PCSK9 inhibitor therapy  
- Ezetimibe therapy  
- Ankle‑Brachial Index (ABI)  
- Asymptomatic PAD  
- Symptomatic PAD  
- Lower extremity bypass grafting  
- Intracranial hemorrhage  
- Bleeding risk (moderate‑to‑severe)  
- PEGASUS‑TIMI 54 trial  
- CHARISMA trial  
- TRA 2P‑TIMI 50 trial  
- CASPAR trial  
- WAVE trial  
- Atrial fibrillation (AF)  
- Venous thromboembolism (VTE)

Page 28 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑intensity statin therapy  
- Statin initiation / continuation  
- Atherosclerotic cardiovascular disease (CVD)  
- Major adverse cardiovascular events (MACE)  
- Major adverse limb events (MALE)  
- Critical limb‑threatening ischemia (CLTI)  
- Endovascular revascularization  
- Surgical revascularization  
- Limb amputation  
- PCSK9 inhibitor  
- Alirocumab  
- Evolocumab  
- FOURIER study (Clinical trial)  
- ODYSSEY OUTCOMES study (Clinical trial)  
- IMPROVE‑IT study (Clinical trial)  
- Atorvastatin (40–80 mg)  
- Rosuvastatin (20–40 mg)  
- Simvastatin (20–40 mg)  
- Pravastatin (40–80 mg)  
- Lovastatin (40–80 mg)  
- Fluvastatin XL (80 mg)  
- Pitavastatin (1–4 mg)  
- Dyslipidemia  
- Primary hypercholesterolemia  
- Mixed dyslipidemia  
- Myopathy (muscle disease)  
- Rhabdomyolysis  
- Acute coronary syndrome (ACS)  
- Vascular Outcomes Study (VOYAGER PAD)  
- Aspirin (acetylsalicylic acid)  
- Rivaroxaban (anticoagulant drug)  

*(All terms are directly related to cardiovascular/heart disease context within the provided guideline text.)

Page 29 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Atherosclerotic arterial disease  
- Major Adverse Cardiovascular Events (MACE)  
- Major Coronary Event  
- Ischemic Stroke  
- Major Adverse Limb Events (MALE)  
- Low‑density lipoprotein (LDL) target <70 mg/dL  
- American Heart Association / American College of Cardiology (AHA/ACC) cholesterol guideline  
- Antihypertensive therapy  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Target blood‑pressure goal <130/80 mm Hg (or <120/80 mm Hg in some trials)  
- Angiotensin‑converting enzyme inhibitors (ACE‑I)  
- Angiotensin‑receptor blockers (ARBs)  
- Hypertension as a cardiovascular risk factor  
- Ankle‑brachial index (ABI)  
- Systolic Blood Pressure Intervention Trial (SPRINT)  
- ABCD (Appropriate Blood Pressure Control in Diabetes) study  
- INVEST (International Verapamil‑SRV Trandolapril) study  
- ALLHAT (Antihypertensive and Lipid‑Lowering Treatment to Prevent Heart Attack Trial)  
- EUCLID trial  
- Heart Outcomes Prevention Evaluation (HOPE) trial  
- Ramipril  
- ONTARGET (Telmisartan Alone and in Combination with Ramipril)  
- Telmisartan  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Heart failure (HF)  
- Left ventricular systolic dysfunction  
- Revascularization procedures  
- Clinical atherosclerotic cardiovascular disease (CVD)  

These terms capture the heart‑disease‑related concepts highlighted in the guideline excerpts.

Page 30 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Cardiovascular disease (CVD)  
- Coronary Artery Disease (CAD)  
- Hypertension  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑receptor blockers (ARBs)  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Stroke  
- Vascular risk factors (e.g., smoking, secondhand smoke)  
- Nicotine replacement therapy  
- Varenicline  
- Bupropion  
- Electronic nicotine delivery systems (e‑cigarettes)  
- Tobacco use/cessation interventions  
- Vascular health outcomes (e.g., limb‑related events, mortality)

Page 31 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Major Adverse Limb Events (MALE)  
- Major Adverse Cardiovascular Events (MACE)  
- Myocardial Infarction (MI)  
- Stroke (non‑fatal)  
- Cardiovascular death  
- Hospitalization for heart failure  
- Glucagon‑like peptide‑1 (GLP‑1) agonists  
- Liraglutide  
- Semaglutide  
- Tirzepatide  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors  
- Canagliflozin  
- Dapagliflozin  
- Empagliflozin  
- Ertugliflozin  
- EMPA‑REG OUTCOME trial  
- CANVAS trial  
- DECLARE‑TIMI 58 trial  
- SUSTAIN‑6 trial  
- LEADER trial  
- Cardiovascular outcomes  
- Non‑fatal MI  
- Non‑fatal stroke  
- Type 2 diabetes  
- Glycemic control  
- Weight management (pharmacologic and non‑pharmacologic therapies for cardiovascular risk)

Page 32 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Peripheral Artery Disease (PAD)  
- Critical Limb Threatening Ischemia (CLTI)  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- canagliflozin  
- empagliflozin  
- SGLT2 inhibitors  
- type 2 diabetes mellitus  
- diabetes mellitus (general)  
- hemoglobin A1c  
- glycemic control  
- cardiovascular risk  
- heart failure  
- revascularization (endovascular/surgical)  
- infra‑popliteal procedures  
- diabetic foot ulcer  
- diabetic neuropathy  
- preprocedural glycemic control  
- ischemic limb outcomes  
- vaccine‑associated vascular complications (influenza, SARS‑CoV‑2)  
- clinical trials: CANVAS, CREDENCE, EMPA‑REG OUTCOME, EUCLID, Strong Heart study  

These terms capture the cardiovascular conditions, risk factors, therapeutic agents, and clinical studies highlighted in the guidelines.

Page 33 Extracted Terms:
Peripheral Artery Disease (PAD)  
Coronary Artery Disease (CAD)  
Cardiovascular Disease (CVD)  
Major Adverse Cardiovascular Events (MACE)  
Influenza vaccination  
SARS‑CoV‑2 vaccination  
Antiplatelet therapy  
Antithrombotic therapy  
Lipid‑lowering therapy  
Antihypertensive therapy  
Smoking cessation  
Diabetes management  
Healthy diet  
Mediterranean diet  
DASH (Dietary Approaches to Stop Hypertension) diet  
PREDIMED study  
Lyon Diet Heart Study  
Vitamin B‑complex supplementation  
Vitamin D supplementation  
Homocysteine  
Chelation therapy  
HOPE‑2 trial (Heart Outcomes Prevention Evaluation‑2)  
TACT trial (Trial to Assess Chelation Therapy)  
Stroke  
Myocardial infarction (MI)  
Recurrent cardiovascular events  
Secondary prevention  
Primary prevention  
Atherosclerotic cardiovascular disease  
Blood pressure  
Sodium reduction  
Blood pressure reduction  
Cardiovascular risk reduction  
Clinical outcomes  

Page 34 Extracted Terms:
**Key heart‑disease related terms identified in the text**

- Peripheral Artery Disease (PAD)  
- Claudication  
- Cilostazol  
- Pentoxifylline  
- Chelation therapy  
- Congestive heart failure (CHF) (any severity)  
- Re‑stenosis (post‑interventional)  
- Endovascular therapy  
- Femoropopliteal disease  
- In‑stent re‑stenosis  
- Bare‑metal femoropopliteal stent  
- Paclitaxel‑eluting stent  
- Major adverse limb event (MALE)  
- Major amputation  
- Major Adverse Cardiac Events (MACE)  
- All‑cause mortality  
- Cardiovascular deaths  
- Cardiovascular disease (CVD)  
- Vitamin D deficiency / hypovitaminosis D  
- Vitamin D supplementation  
- Phosphodiesterase III inhibitor  
- Milrinone (phosphodiesterase inhibitor)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Cardiovascular risk/vascular risk  
- ABI (ankle‑brachial index) – vascular health indicator  
- PAQ (Peripheral Artery Questionnaire) – assessment of limb function  
- QOL (quality of life) – health outcome metric  
- Walking distance / maximal walking distance – functional capacity metric

Page 35 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Cardiovascular Disease (CVD)  
- Coronary Artery Disease (CAD)  
- Heart Failure  
- Cerebrovascular Disease  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Endovascular revascularization  
- Surgical revascularization  
- Vascular specialists  
- Claudication (leg pain on walking)  
- Rest pain (ischemic pain at rest)  
- Clotting or thrombosis of peripheral arteries (implied by PAD discussion)  
- Chronic Kidney Disease (CKD) – a major cardiovascular comorbidity  
- End‑Stage Kidney Disease (ESKD) – an extreme CKD stage linked to vascular disease  
- Diabetes with poor glycemic control – a key modifiable risk factor for cardiovascular disease  
- Peripheral neuropathy – a neurological complication often secondary to vascular disease  
- Charcot foot deformity – a severe complication of PAD with cardiovascular implications  
- Foot ulceration and amputation – sequelae of advanced peripheral arterial disease and systemic vascular compromise  
- Therapeutic footwear – a preventive strategy to reduce cardiovascular‑related foot ulceration risk  
- Foot self‑care education – a non‑pharmacologic intervention to mitigate cardiovascular complications associated with PAD  

(Note: All terms are derived directly from the text and pertain to heart or cardiovascular disease concepts.)

Page 36 Extracted Terms:
**Key terms related to heart disease (and vascular complications) in the guideline:**

- Peripheral Artery Disease (PAD)  
- Foot ulcers  
- Foot care / self‑foot care  
- Foot inspection / foot surveillance  
- Foot deformities (e.g., bunions/hallux valgus, hammertoe, claw toe, flatfoot/pes planus, severe high‑arch foot/pes cavus, Charcot foot, arthritic foot)  
- Protective footwear / therapeutic footwear  
- Podiatry / podiatrist  
- Revascularization  
- Multispecialty care team  
- Exercise therapy for PAD  
- Lower extremity amputation  
- Walking performance / functional status  
- Diabetes‑associated neuropathy  
- Foot temperature monitoring  
- Foot education resources (American Diabetes Association, CDC, NIDDK)  
- Risk‑based foot screening intervals (annual, every 3–6 months, every 1–3 months)  

These terms capture the primary concepts, interventions, and complications discussed in the guideline that relate to vascular health and, by extension, heart‑related disease processes.

Page 37 Extracted Terms:
- Peripheral artery disease (PAD)  
- Claudication  
- Revascularization  
- Supervised Exercise Therapy (SET)  
- Structured community‑based exercise program  
- Home‑based exercise program  
- Walking performance  
- Functional status  
- Quality of life (QOL)  
- Endothelial function  
- Endothelial dysfunction  
- Angiogenesis  
- Microvascular blood flow  
- Macrovascular blood flow  
- Ischemia‑reperfusion injury  
- Intermittent walking  
- Treadmill training  
- Stationary bicycle training  
- Arm ergometry  
- Recumbent stepping  
- Behavioral change techniques  
- Activity monitors  
- Clinical exercise physiologists  
- Nurses with exercise training experience  
- Cardiac rehabilitation  
- Medicare coverage of exercise therapy  
- Commercial insurance coverage of exercise therapy  
- Muscle fiber adaptations  
- Mitochondrial density and activity  
- Skeletal muscle strength and endurance  
- Blood distribution efficiency  
- Local inflammatory response  
- Ischemic symptoms (moderate‑to‑severe claudication pain)  
- Pain‑induced rest periods  
- Incremental increases in walking intensity  
- Progressive training to 30‑45 min of active walking  
- Exercise session duration (30‑45 min per 60‑min session)  
- Exercise session frequency (≥3 sessions per week)  
- Minimum training duration (≥12 weeks)  
- Walking distance and speed progression  
- Exercise prescription alterations  
- Monitoring of exercise progress  
- Patient counseling and education  
- Behavioral coaching (in‑person or virtual)  
- Home or community setting for exercise  
- Hospital or outpatient facility setting for exercise  
- Structured exercise program classification  
- Exercise adherence and adherence strategies  
- Cardiovascular health interventions  
- Physical activity promotion  
- Exercise therapy for cardiovascular disease management

Page 38 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Claudication  
- Supervised Exercise Therapy (SET)  
- Structured community‑based exercise programs  
- Revascularization  
- Treadmill walking  
- 6‑Minute Walk Test (6MWT)  
- Walking performance  
- Functional status  
- Quality of Life (QOL)  
- Cardiac rehabilitation  
- Exercise‑limiting cardiovascular disease (CVD)  
- Amputation  
- Wheelchair confinement  
- Diabetes (as a PAD comorbidity)  
- Home‑based exercise programs  
- Virtual coaching  
- Activity tracking  
- Behavioral change techniques  
- Health coaching  
- LITE (Low Intensity Exercise Intervention in PAD) trial  
- GOALS (Group Oriented Arterial Leg Study)  
- Medicare coverage of SET  
- Insurance reimbursement for exercise therapy  
- Exercise prescription parameters (treadmill walking parameters, 6MWT)  
- Evidence‑based risk–benefit ratio for SET in PAD  

Page 39 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Intermittent Claudication  
- Supervised Exercise Therapy (SET)  
- Structured Exercise Programs  
- Community‑Based Exercise  
- Home‑Based Walking Program  
- 6‑Minute Walk Test (6MWT)  
- Quality of Life (QOL)  
- Percutaneous Transluminal Angioplasty (PTA)  
- Endovascular Revascularization  
- Endoluminal Revascularization  
- Femoropopliteal Disease  
- Aortoiliac PAD  
- Revascularization + SET Combination Therapy  
- Alternative Exercise Modalities (cycling, recumbent stepping, resistance training)  
- Treadmill Walking (low‑intensity vs. moderate/high‑intensity)  
- Functional Status Improvement  
- Pain Levels (moderate to severe claudication pain)  
- Structured Community‑Based Exercise Programs (including home‑based)  
- Unstructured Exercise (self‑directed walking)  
- Exercise‑Induced Ischemic Symptoms  

(Note: These terms represent the primary disease‑condition, therapeutic modalities, outcome measures, and exercise strategies mentioned in the text.)

Page 40 Extracted Terms:
**Key terms related to heart disease**

- Peripheral Artery Disease (PAD)  
- Asymptomatic PAD  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Acute Limb Ischemia (ALI)  
- Claudication  
- Endovascular revascularization procedures  
- Surgical revascularization procedures  
- Transfemoral aortic valve replacement  
- Mechanical circulatory support  
- Endovascular aortic aneurysm repair  
- Endovascular stenting  
- Endoconduit creation  
- Iliac artery conduit  
- Iliofemoral bypass  
- Catheter‑based cardiac procedures  
- Catheter insertion and removal  
- Safety of sheath insertion  
- Major Adverse Limb Events (MALE)  
- Vascular complications  
- Cardiovascular Angiography and Interventions (SCAI)  
- Vascular Quality Initiative (VQI)  
- National Cardiovascular Data Registry (NCDR)  
- Society of Interventional Radiology (SIR)  
- PVI Registry (Peripheral Vascular Intervention)  
- VIRTEX Registry  
- Endovascular therapies (general)  
- Conduit placement (general)

Page 41 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Symptomatic PAD  
- Claudication (exertional leg symptoms)  
- Rest pain  
- Critical Limb-threatening Ischemia (CLTI)  
- Revascularization (endovascular, surgical, hybrid)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Quality of Life (QOL)  
- Foot care  
- Exercise therapy for PAD  
- Patient outcomes  
- Local quality improvement initiatives  
- Benchmarking across centers  
- Revascularization procedures  
- Tracking of revascularization procedures  
- Professional societies (guideline authors)

Page 42 Extracted Terms:
**Key terms related to heart disease / cardiovascular care:**

- Peripheral arterial disease (PAD)
- Claudication
- Revascularization
- Endovascular revascularization
- Surgical revascularization
- Aortoiliac disease
- Femoro‑popliteal disease
- Common femoral artery disease
- Infrapopliteal disease
- Hemodynamically significant lesion
- Glucose‑lowering medical therapy (GDMT) – often including antihypertensive, lipid‑lowering, antiplatelet agents
- Structured exercise therapy
- Quality of life (QOL)
- Walking performance / functional status
- Major adverse cardiovascular events (MACE)
- Bleeding
- Infection
- Perioperative risk
- Endovascular techniques:
  - Percutaneous transluminal angioplasty (PTA / balloon angioplasty)
  - Drug‑coated balloon angioplasty
  - Bare‑metal stents
  - Drug‑eluting stents
  - Covered stents
  - Lithotripsy (intravascular lithotripsy)
  - Atherectomy
- Intravascular pressure measurements
- Resting vs. provoked pressure gradients
- Anatomical evaluation of disease
- Longitudinal follow‑up
- Diagnostic testing for PAD
- Patient‑centered decision making
- Patient engagement
- Smoking cessation
- Medication adherence

These terms capture the cardiovascular concepts, therapeutic options, outcomes, and patient‑care considerations present in the guideline excerpt.

Page 43 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Claudication  
- Surgical revascularization  
- Endarterectomy  
- Bypass (vascular bypass)  
- Endovascular treatment  
- Hybrid approaches (combined surgical/endovascular)  
- Guideline‑Directed Medical Therapy (GDMT)  
- Structured exercise (SET)  
- Pain‑free walking distance  
- Total walking distance  
- Quality of Life (QOL)  
- Diabetes mellitus  
- End‑stage kidney disease (ESKD)  
- Obesity  
- Frailty  
- Functional status  
- Major adverse limb events (MALE)  
- Restenosis  
- Acute limb ischemia (ALI)  
- Critical limb‑threatening ischemia (CLTI)  
- Anterior aortoiliac disease  
- Femoropopliteal disease  
- Critical limb ischemia (CLI)  
- Long‑term durability of revascularization  
- Reintervention risk  
- Readmission risk  
- Randomized controlled trials (RCTs)  
- Network meta‑analysis  

These terms capture the major concepts and clinical factors related to heart (cardiovascular) disease discussed in the provided guideline excerpt.

Page 44 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Endovascular Treatment  
- Endovascular Revascularization  
- Endovascular Therapy  
- Endovascular Intervention  
- Claudication  
- Supervised Exercise Therapy (SET)  
- Walking Performance  
- Walking Distance  
- Quality of Life (QOL)  
- Vessel Patency  
- Primary Patency  
- Secondary Patency  
- Aortoiliac Segment  
- Femoropopliteal Segment  
- Aortoiliac Disease  
- Femoropopliteal Disease  
- Occlusion  
- Stenosis  
- Lesion Length  
- Multiple Lesions  
- Diffuse Lesions  
- Poor-Quality Runoff  
- Diabetes Mellitus  
- Chronic Kidney Disease (CKD)  
- Renal Failure  
- Smoking  
- Guideline-Directed Medical Therapy (GDMT)  
- Medical Therapy  
- Medications Alone  
- Surgical Revascularization  
- Endarterectomy  
- Common Femoral Endarterectomy  
- Perioperative Risk  
- Major Adverse Cardiovascular Events (MACE)  
- Reintervention  
- Restenosis  
- Durability  
- Patency Rates  
- Complications  
- Wound Infection  
- Lymphatic Fistula  



Page 45 Extracted Terms:
- Peripheral arterial disease (PAD)  
- Claudication  
- Critical limb ischemia (CLTI)  
- Endovascular revascularization  
- Open surgical revascularization  
- Endarterectomy  
- Autogenous vein graft (e.g., great saphenous vein)  
- Prosthetic conduit (prosthetic graft material)  
- Femoropopliteal bypass  
- Popliteal artery  
- Common femoral artery  
- Aorto‑iliac lesions  
- Infra‑popliteal disease  
- Bypass graft patency  
- Multispecialty, team‑based care for PAD  
- Revascularization as standard therapy for CLTI  
- Wound care, infection management, and pressure off‑loading as adjuncts  
- Structured exercise (comparative treatment option)  

These terms capture the core cardiovascular concepts discussed in the guideline excerpt.

Page 46 Extracted Terms:
- Chronic limb‑threatening ischemia (CLTI)  
- Peripheral artery disease (PAD)  
- Multi‑specialty care team  
- Revascularization techniques  
- Vascular care  
- Wound‑healing therapies  
- Podiatry  
- Foot surgery  
- Guideline‑directed medical therapy (GDMT)  
- Quality of life (QOL)  
- Comprehensive care  
- Wound healing  
- Prevention of amputation  
- Tissue loss  
- Ambulatory status  
- Multidisciplinary approaches  
- Vascular revascularization  
- Patient‑centered care  

Page 47 Extracted Terms:
- Chronic Limb-Threatening Ischemia (CLTI)  
- Peripheral Artery Disease (PAD)  
- Revascularization  
- Surgical revascularization  
- Endovascular revascularization  
- Hybrid revascularization  
- Bypass  
- Autogenous vein  
- Great saphenous vein  
- Ultrasound mapping  
- Prosthetic graft  
- Cadaveric graft  
- Popliteal artery  
- Infrapopliteal arteries (tibial, pedal)  
- Inflow disease  
- Outflow disease  
- In-line blood flow  
- Perfusion  
- Tissue loss  
- Wound healing  
- Nonhealing wounds  
- Gangrene  
- Ischemic rest pain  
- Limb‑threatening infection  
- Amputation  
- Multispecialty care team  
- Vascular medicine  
- Vascular surgery  
- Vascular interventional radiology  
- Interventional cardiology  
- Endovascular specialist  
- Surgical specialist  
- Nurse practitioner / physician assistant  
- Nurse  
- Podiatrist  
- Orthopedic surgeon  
- Foot surgeon  
- Wound‑care specialist  
- Endocrinologist  
- Internal medicine specialist  
- Infectious disease specialist  
- Diagnostic radiologist  
- Vascular imaging specialist  
- Pharmacist  
- Physical medicine and rehabilitation clinician  
- Occupational therapist  
- Physical therapist  
- Clinical exercise physiologist  
- Nutritionist / dietitian  
- Social worker  
- Patients and family members (care coordination)

Page 48 Extracted Terms:
**Key heart‑disease related terms**

- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization  
- Endovascular therapy  
- Surgical revascularization  
- Hybrid revascularization  
- Bypass surgery  
- Angioplasty  
- Endarterectomy  
- Autogenous vein conduit  
- Saphenous vein  
- Coronary artery bypass surgery  
- Coronary ischemia  
- Cardiomyopathy  
- Heart failure  
- Major adverse cardiac events (MACE)  
- BEST‑CLI (trial)  
- BASIL‑2 (trial)  

These terms capture the cardiovascular interventions, conditions, and trial identifiers that are central to the guideline’s discussion of heart‑related disease.

Page 49 Extracted Terms:
1. Revascularization  
2. Endovascular intervention  
3. Surgical bypass  
4. Critical Limb Ischemia (CLTI)  
5. Peripheral Artery Disease (PAD)  
6. Autogenous vein  
7. Great saphenous vein  
8. Small saphenous vein  
9. Basilic vein  
10. Cephalic vein  
11. Composite bypass conduit  
12. Popliteal artery  
13. Infrapopliteal disease  
14. BASIL‑2 trial (Bypass versus Angioplasty for Severe Ischaemia of the Leg)  
15. BEST‑CLI trial (Best-CLI)  
16. Global Limb Anatomic Staging System (GLASS)  
17. Major Adverse Limb Events (MALE)  
18. Major amputation  
19. Graft thrombectomy  
20. Graft revision  
21. Thrombolysis  
22. Patency  
23. Duplex ultrasound  
24. Vein mapping  
25. Vascular laboratory  
26. Preoperative assessment of vein adequacy  
27. Vein conduit suitability  
28. Anatomic pattern of disease  
29. Multidisciplinary care team  
30. Risk‑benefit calculation.

Page 50 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization  
- Inflow lesions  
- Outflow lesions  
- Autogenous vein graft  
- Prosthetic bypass graft  
- Saphenous vein (autogenous conduit)  
- Cadaveric vein graft  
- Endovascular intervention  
- Endovascular therapy  
- Surgical bypass  
- Angiosome (direct pulsatile flow)  
- Collateral circulation  
- Limb salvage  
- Wound healing  
- Ischemic rest pain  
- Multilevel disease  
- Pressure offloading  
- Diabetic foot ulcer  
- Customized footwear (pressure‑offloading)  
- Duplex ultrasound (vascular laboratory)  
- Point‑of‑care ultrasound  
- Vascular laboratory  
- Vascular conduit  
- Hemodynamic blood flow to foot  
- Perfusion to the wound bed  
- Pulse flow (direct revascularization)  
- Vascular laboratory‑based duplex ultrasound  

(These terms capture the key cardiovascular and vascular concepts discussed in the guideline excerpt.)

Page 51 Extracted Terms:
**Key heart‑vascular terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization  
- Pressure offloading devices (non‑removable vs removable)  
- Hyperbaric oxygen therapy  
- Negative pressure wound therapy (NPWT)  
- Minor and major amputation (foot, digit)  
- Surgical debridement (for foot infections/gangrene)  
- Foot ulcer management (including diabetic foot ulcers)  
- Antimicrobial therapy for foot infections  
- Multidisciplinary wound‑care team (for CLTI)  

These terms capture the cardiovascular and peripheral‑vascular focus of the guideline text.

Page 52 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Endovascular revascularization  
- Limb salvage  
- Venous arterialization  
- Arterial intermittent pneumatic compression devices  
- Prostanoids (in the context of CLTI)  
- Ischemia  
- Revascularization (when not an option)  
- Hyperbaric oxygen therapy  
- Cardiovascular risk factor modification  
- Wound healing in PAD/CLTI  
- Pressure offloading  
- Pain control (for ischemic rest pain)  
- Smoking cessation  
- Glycemic control (diabetes management)  
- Multispecialty care team (vascular, wound care, cardiology)  
- Endovascular therapy for PAD  
- Ankle‑Brachial Index (ABI) <0.80  
- Toe‑Brachial Index (TBI) <0.70  
- Limb‑preservation strategies  
- Tissue growth optimization  
- Edema control  
- Infection management in PAD patients

Page 53 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

- Cardiovascular mortality  
- Vascular endothelial cytoprotection  
- Vasodilation  
- Platelet aggregation inhibition  
- Nitric‑oxide release  
- Prostanoids (prostacyclin, iloprost)  
- Endovascular revascularization  
- Intermittent pneumatic compression device (arterial pump)  
- Arteriovenous pressure gradient  
- Reversal of vasomotor paralysis  
- Chronic limb‑threatening ischemia (CLTI)  
- Peripheral artery disease (PAD)  
- Limb salvage rate  
- Wound healing (vascular component)  
- Anatomic classification of limb ischemia (GLASS/WIfI)

Page 54 Extracted Terms:
**Key Heart‑Disease–Related Terms Extracted**

1. Peripheral Artery Disease (PAD)  
2. Critical Limb Ischemia / Critical Limb Threatening Ischemia (CLTI)  
3. Ischemia  
4. Revascularization  
5. Venous Arterialization  
6. Percutaneous Deep Vein Arterialization (pDVA)  
7. Hybrid techniques (open, percutaneous, or combined)  
8. Limb salvage  
9. Amputation‑free survival  
10. Major amputation  
11. Minor amputation (inframalleolar level)  
12. Wound healing / complete wound healing  
13. Infection (advanced or bone/soft‑tissue involvement)  
14. Inflammation / metabolic derangement  
15. Prosthetic rehabilitation / ambulation  
16. Quality of Life (QOL) outcomes in limb loss  
17. Multispecialty care team / team‑based care for CLTI  
18. Objective limb‑threat classification tools  
19. AHA (American Heart Association) non‑traumatic amputation reduction goal  
20. Cardiovascular risk factors implied by “ischemia” and “revascularization”  

These terms capture the cardiovascular‑focused concepts presented in the guideline excerpt.

Page 55 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Critical Limb‑Threatening Ischemia (CLTI)  
- Cardiovascular Disease (CVD)  
- Revascularization (interventional/surgical)  
- Ischemia (vascular‑related tissue hypoxia)  
- WIfI (Wound‑Ischemia‑Foot‑Infection) classification tool  
- GLASS (Global Limb Anatomic Staging System) classification tool  
- Advanced CVD (as a reference to severe cardiovascular disease)

Page 56 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Acute Limb Ischemia (ALI)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization (endovascular or surgical)  
- Coronary Artery Bypass Grafting (CABG)  
- Valve Surgery  
- Percutaneous Coronary Intervention (PCI)  
- Myocardial Infarction (MI)  
- WIfI classification (Wound, Ischemia, foot Infection)  
- GLASS classification (Global Limb Ankle and Foot Severity Score)  
- Vascular Quality Initiative (VQI)  
- National Cardiovascular Data Registry (NCDR) – PVI Registry  
- Society of Interventional Radiology VIRTEX registry  
- Society of Thoracic Surgery (STS) reporting  
- Limb Viability  
- Limb Salvage  
- Ischemia  
- Endovascular Procedures  
- Duplex Ultrasound  
- Computed Tomography Angiography (CTA)  
- Magnetic Resonance Angiography (MRA)  
- Continuous Wave Doppler (limb assessment)

Page 57 Extracted Terms:
**Key heart‑disease related terms**

- Peripheral artery disease (PAD)  
- Acute limb ischemia (ALI)  
- Revascularization (surgical or endovascular)  
- Cardiovascular (CV)  
- Aortic dissection  
- Bypass graft  
- Stent (endovascular stenting)  
- Ischemia  
- Thrombosis  
- Embolus  
- Duplex ultrasound  
- Computed tomography angiography (CTA)  
- Magnetic resonance angiography (MRA)  
- Doppler ultrasonography (continuous‑wave Doppler)  
- Electrocardiogram (ECG)  
- Morbidity and mortality (cardiovascular outcomes)

Page 58 Extracted Terms:
**Key terms related to heart disease (vascular/ischemic disease) extracted from the guideline text**

- Acute Limb Ischemia (ALI)  
- Salvageable limb  
- Non‑salvageable limb  
- Revascularization  
- Endovascular revascularization  
- Surgical revascularization  
- Catheter‑directed thrombolysis  
- Catheter‑based thrombolysis  
- Ultrasound‑accelerated thrombolysis  
- Pharmacomechanical thrombectomy  
- Vacuum‑assisted percutaneous mechanical thrombectomy  
- Endovascular thromboembolectomy  
- Surgical thromboembolectomy (e.g., Fogarty catheter)  
- Bypass graft occlusion  
- Retained valves  
- Neointimal hyperplasia  
- Diffuse atherosclerotic lesions  
- Focal atherosclerotic lesions  
- Patch angioplasty  
- Jump extension grafts  
- Interposition grafts  
- Endarterectomy  
- Percutaneous transluminal angioplasty (PTA)  
- Stenting (endovascular stent)  
- Compartment syndrome  
- Reperfusion injury  
- Limb salvage  
- Major amputation  
- Mortality (high rates of mortality associated with ALI)  
- Limb loss  
- Chemotherapeutic‑induced prothrombotic viral states  
- Catheter‑based mechanical thrombectomy  
- Lytic agent (used in thrombolysis)  
- Revascularization strategy  
- Culprit lesion  
- Catheter‑directed thrombolysis efficacy vs. open surgery  
- Revascularization planning strategy  
- Adjuvant (adjunctive) revascularization procedures  
- Revascularization indications (categories I, IIa, IIb)  

These terms capture the key clinical concepts, procedures, and risk factors discussed in the guideline excerpt.

Page 59 Extracted Terms:
- Acute limb ischemia (ALI)  
- Peripheral artery disease (PAD)  
- Thrombolysis  
- Revascularization (endovascular or surgical)  
- Catheter‑directed thrombolysis  
- Anticoagulation  
- Unfractionated heparin  
- Thrombotic events  
- Tyrosine kinase inhibitors  
- Cancer chemotherapy (platinum‑based agents)  
- Prothrombotic states  
- Systemic proinflammatory states  
- COVID‑19 / SARS‑CoV‑2 infection  
- Multiorgan failure  
- Cardiovascular collapse  
- Ischemia (irreversible, prolonged)  
- Reperfusion injury  
- Oxygen‑free radicals  
- Compartment syndrome  
- Compartment pressures  
- Creatine kinase elevation  
- Collateral circulation  
- Limb loss  
- Amputation  
- Prophylactic fasciotomy  
- Reperfusion metabolites  
- Endovascular techniques  
- Surgical bypass  
- Clinical stability and comorbidities  
- Multidisciplinary discussion (treatment approach)

Page 60 Extracted Terms:
- Coronary artery disease (CAD)  
- Heart failure  
- Aortic dissection  
- Cardiac thromboembolism (cardiovascular cause of thromboembolism)  
- Ischemia (e.g., myocardial or limb ischemia)  
- Reperfusion syndrome  
- Reperfusion injury  
- Anticoagulation therapy  
- Unfractionated heparin  
- Direct thrombin inhibitor  
- Thrombus  
- Embolism  
- Revascularization procedures  
- Vascular (cardiovascular) disease  
- Compartment syndrome (associated with ischemic injury)

Page 61 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Acute Limb Ischemia (ALI)  
- Atrial fibrillation  
- Myocardial infarction (MI)  
- Cardiomyopathy  
- Valvular heart disease  
- Mitral stenosis  
- Left atrial thrombus / left atrial appendage thrombus  
- Left ventricular thrombus  
- Infective endocarditis (valvular vegetation)  
- Intracardiac shunt (e.g., patent foramen ovale)  
- Intracardiac mural thrombi  
- Transient ischemic attack / stroke (as a cardiac embolic event)  
- Heart rhythm disturbances (irregular rhythm, arrhythmia)  
- Palpitations  
- Tachycardia  
- Chest pain (cardiac origin)  
- Congestive heart failure  
- Cardiac murmur  
- Electrocardiography (ECG)  
- Cardiac rhythm monitoring (e.g., Holter, event recorder)  
- Echocardiography (transthoracic / transesophageal)  
- Cardiac embolization mechanisms  
- Anticoagulation therapy for atrial fibrillation  
- Anticoagulation monitoring (last dose, INR, etc.)  
- Cardiac causes of thromboembolic disease (e.g., left atrial thrombus, valvular vegetations, intracardiac shunts)  
- Cardiac-related pulmonary symptoms (e.g., dyspnea, pulmonary edema)  
- Cardiac evaluation in acute limb ischemia management

These terms represent the primary concepts in the source text that are associated with heart disease.

Page 62 Extracted Terms:
- Atrial fibrillation  
- Valvular disease  
- Intracardiac thrombus  
- Mitral stenosis  
- Cardioembolic cause (e.g., AF, stenosis, thrombus)  
- Thrombus (aortic)  
- Aortic aneurysm (imaging of the aorta)  
- Hypercoagulable states  
- Major adverse cardiovascular events (MACE)  
- Myocardial infarction (MI)  
- Stroke  
- Death  
- Guideline‑directed medical therapy (GDMT)  
- Cardiovascular risk factors  
- Cardiovascular and limb risk reduction efforts  

Page 63 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Critical Limb Ischemia (CLTI)  
- Major Adverse Cardiovascular Events (MACE)  
- Myocardial Infarction (MI)  
- Ischemic Stroke  
- Guideline‑Directed Medical Therapy (GDMT)  
- Lipid‑lowering therapy  
- Statin therapy  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Blood‑pressure control  
- Diabetes mellitus  
- Hypertension  
- Dyslipidemia  
- Smoking cessation  
- Cardiovascular risk factors  
- Ankle‑Brachial Index (ABI)  

Page 64 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Restenosis  
- Revascularization (endovascular and surgical)  
- Duplex ultrasound surveillance  
- Infrainguinal autogenous vein bypass grafts  
- Prosthetic bypass grafts  
- Low flow (graft compromise indicator)  
- Stenosis (severe)  
- Aortoiliac, femoropopliteal, infrapopliteal vessel segments  
- Critical Limb-Threatening Ischemia (CLTI)  
- Acute Limb Ischemia (ALI)  
- Telehealth (virtual visits for vascular care)  
- Symptomatic PAD (claudication, ischemia-related exertional symptoms)  
- Asymptomatic PAD screening  
- Cardiovascular risk reduction therapies  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Antiplatelet and antithrombotic regimens  
- Supervised Exercise Training (SET)  
- Functional status / walking performance metrics  
- Endovascular devices: balloon angioplasty, drug-coated balloon angioplasty, atherectomy  
- Shared decision‑making strategies in PAD management  
- Wound healing and limb salvage strategies for CLTI  
- Comparative effectiveness studies of revascularization strategies.

Page 65 Extracted Terms:
Peripheral Artery Disease (PAD)  
Chronic Limb‑Threatening Ischemia (CLTI)  
Cardiovascular Disease (CVD)  
Coronary Artery Disease (CAD)  
Revascularization  
Guideline‑Directed Medical Therapy (GDMT)  
Structured Exercise Training (SET)  
Telehealth  
Remote Patient‑Monitoring Devices (wearables, smart devices)  
Nontraumatic Lower Extremity Amputation  
Limb Outcomes  
Cardiovascular Outcomes  
Risk Factor Modification  
Smoking Cessation  
Detection  
Diagnosis  
Clinical Outcomes  
Readmissions  
Hybrid Programs (facility‑based & community/home‑based)  
National Registry of Nontraumatic Amputations  
PAD National Action Plan  
AHA Get With The Guidelines  
Multispecialty / Multisocietal Collaboration  
Advocacy Priorities  
Disparities (in care, outcomes, access)  
Prevention  
Telemedicine  
Wearable Technology  
Smart Devices  
Peripheral Vascular Surveillance Testing  
Quality Outcomes  
Access to Care  
Affordability  
Telehealth Implementation  
Remote Monitoring  
Risk Factor Identification  
Clinical Surveillance  
Regulatory Support  
Public Health Initiative  
Evidence‑Based Interventions  
Healthcare Disparity Gap  
Medical Therapy Optimization  
Lifestyle Modification  
Outpatient Follow‑up  
Revascularization Readmissions  
Clinical Surveillance Programs  
Patient‑Engagement Tools  
Digital Health Platforms  
Population‑Based Data Collection  
Registry‑Based Research  
Outcome Tracking  
Policy Development  
Care Coordination  
Data‑Driven Quality Improvement.

Page 66 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower extremity peripheral artery disease  
- Cardiovascular disease (CVD)  
- Cardio‑vascular disease and comorbid conditions  
- Coronary artery disease (inferred from dual antiplatelet therapy context)  
- Dual antiplatelet therapy  
- Perioperative cardiovascular evaluation  
- Non‑cardiac surgery (perioperative context)  
- Heart disease (general term)  
- Stroke (as a major cardiovascular comorbidity)

Page 67 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular disease  
- Heart disease  
- Chronic coronary disease  
- Stroke  
- Hypertension  
- Blood cholesterol  
- Atherosclerosis  
- Atherosclerotic occlusive disease  
- Chronic limb‑threatening ischemia  
- Critical limb ischemia  
- Lower extremity ischemia  
- Aorto‑iliac arterial intervention  
- Ankle‑brachial index  
- Claudication  
- Endovascular intervention  
- Ischemia  
- Diabetes mellitus  
- Smoking cessation  
- Atherosclerotic vascular disease  
- Wound, Ischemia, and Foot Infection (WIfI) classification  
- Lower extremity threatened limb  
- Angiosomes  
- Lower extremity  
- Coronary disease  
- Cardiovascular disease prevention  
- Telehealth in cardiovascular disease  
- Acute limb ischemia

Page 68 Extracted Terms:
- Peripheral Artery Disease (PAD)    
- Lower‑Extremity Arterial Disease    
- Ankle‑Brachial Index (ABI)    
- Intermittent Claudication    
- Chronic Limb‑Threatening Ischemia    
- Critical Limb Ischemia    
- Lower‑Extremity Ischemia    
- Wound, Ischemia, and Foot Infection (WIfI) Classification    
- Atherosclerosis    
- Coronary Artery Disease    
- Vascular Morbidity    
- Vascular Mortality    
- Non‑invasive Testing (e.g., Doppler, Ultrasound)    
- Resting ABI    
- Endovascular Therapy    
- Surgical Revascularisation    
- Amputation    
- Physical Examination (pulse palpation)    
- Pulse Palpation    
- Family History (of peripheral artery disease)    
- Risk Stratification    
- Clinical Data Standards (for peripheral atherosclerotic disease)    
- American Heart Association (AHA) Guidelines    
- American College of Cardiology (ACC) Guidelines

Page 69 Extracted Terms:
- Peripheral Arterial Disease (PAD)  
- Ankle‑Brachial Index (ABI)  
- Toe‑Brachial Index (TBI)  
- Critical Limb Ischemia (CLI)  
- Carotid Atherosclerosis  
- Cerebrovascular Accident (Stroke)  
- Transient Ischemic Attack (TIA)  
- Cardiovascular Disease (CVD)  
- Coronary Heart Disease  
- Atherosclerotic Disease  
- Exercise Treadmill Test  
- 6‑Minute Walk Test  
- Non‑Invasive Vascular Assessment  
- Transcutaneous Oxygen Pressure (TcPO₂)  
- Skin Perfusion Pressure (SPP)  
- Continuous‑Wave Doppler  
- Photoplethysmography  
- Risk Assessment  
- Framingham Risk Score  
- Chronic Kidney Disease (CKD)  
- Diabetes Mellitus  
- Vascular Events  
- Major Amputation  
- Revascularization  
- Endovascular Intervention  
- Clinical Outcomes  
- Functional Status  
- Systolic Blood Pressure  
- Segmental Systolic Pressures  
- Peripheral Occlusive Disease  
- Wound, Ischemia, Foot Infection (WIfI) Classification  
- Arterial Stenosis  
- Arterial Occlusion  
- Ischemic Limb  
- Peripheral Vascular Disease  
- Cardiovascular Events  
- Angiography  
- Duplex Ultrasound  
- Vascular Screening  
- Risk Stratification  
- Pulse Wave Analysis  

Page 70 Extracted Terms:
**Key heart‑/vascular‑disease terms extracted from the guideline text**

- Peripheral artery disease (PAD)  
- Ankle‑brachial index (ABI)  
- Cardiovascular disease (CVD)  
- Endovascular revascularization  
- Critical limb ischemia (CLI)  
- Lower extremity arterial disease  
- Vascular assessment (photoplethysmography, laser Doppler flowmetry, duplex ultrasonography, CT angiography, MR angiography, angiography)  
- Antiplatelet therapy  
- Lipid‑lowering therapy  
- Tobacco use / cessation  
- Diabetes mellitus (type 1 & type 2)  
- Diabetic foot ulcer (DFU)  
- Amputation risk  
- Renal insufficiency / chronic kidney disease (CKD)  
- Contrast‑induced nephropathy  
- Nephrogenic systemic fibrosis (NSF)  
- Gadolinium‑based contrast agents  
- Iodinated contrast media  
- Radiographic contrast media safety  
- Stroke risk (via PAD as a marker)  
- Mortality risk in PAD patients  
- Endovascular disease progression  
- Lower limb wound healing  

These terms capture the cardiovascular, diagnostic, therapeutic, and risk‑factor elements relevant to heart disease discussed in the guideline.

Page 71 Extracted Terms:
- Peripheral artery disease  
- Coronary artery disease  
- Atherosclerosis  
- Myocardial infarction  
- Stroke  
- Cerebrovascular disease  
- Acute coronary syndromes  
- Polyvascular disease  
- Cardiovascular risk factors  
- Atherosclerotic cardiovascular disease  
- Cardiovascular events  
- Cardiovascular outcomes  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiovascular and limb outcomes  
- Heart disease  
- Critical limb ischemia  
- Microvascular disease

Page 72 Extracted Terms:
**Key terms related to heart disease**

- Peripheral artery disease  
- Lower‑extremity peripheral artery disease  
- Nontraumatic lower‑extremity amputation  
- Racial disparities in peripheral artery disease  
- Socioeconomic status  
- Ankle‑brachial index  
- Coronary heart disease  
- Vascular disease  
- Structural heart disease  
- Congenital heart disease  
- Cardiovascular health  
- Cardio‑vascular outcomes  
- Revascularization  
- Amputation  
- Diabetes mellitus  
- Risk factors for peripheral artery disease  
- Sex differences in peripheral artery disease  
- Female‑sex cardiovascular risk  
- Disparities in care  
- Allostatic load  
- Health disparities  
- Public policy for cardiovascular disease  
- American Heart Association guidelines  
- Scientific statement  
- Policy statement  
- Epidemiology  
- Clinical characteristics  
- Leg symptoms  
- Lower extremity functioning  
- Supervised exercise therapy  
- Medicare beneficiaries  
- Amputation rates  
- Racial and ethnic disparities in cardiovascular risk  
- Structural racism  
- Minority communities  
- Amputation prevention  
- Nontraumatic amputation  
- Treatment of vascular disease

Page 73 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Cardiovascular Disease (CVD)  
- Cardiovascular Events  
- Myocardial Infarction (MI)  
- Stroke  
- Antiplatelet Therapy  
- Antithrombotic Therapy  
- Aspirin (ASA)  
- Clotting / Thrombosis  
- Atherosclerosis  
- Chronic Limb‑Threatening Ischemia  
- Critical Limb Ischemia (CLI)  
- Lower Extremity Amputation (Amputation, Major Amputation)  
- Bypass Grafting (Open Bypass Surgery)  
- Endovascular Therapy (Endovascular Revascularization)  
- Ankle‑Brachial Index (ABI)  
- Angiography / Vascular Imaging  
- Lipid Management / Statins  
- Blood Pressure Management (Hypertension)  
- Diabetes‑Related Vascular Disease  
- Socioeconomic Deprivation / Rurality Impact on CVD  
- Frailty and Sarcopenia (muscle loss)  
- Functional Status / Mobility Limitations  
- Mortality (Short‑ and Long‑Term)  
- Revascularization (Surgical & Endovascular)  
- Antiplatelet Agents (Clopidogrel, Ticagrelor, etc.)  
- Anticoagulation (Heparin, Warfarin, DOACs)  
- Cardiovascular Prevention Guideline (ACC/AHA, ESC)  
- Clinical Outcomes (Major Adverse Cardiovascular Events – MACE)  
- Lifestyle Modifications (Smoking Cessation, Physical Activity)  
- Nutritional Status / Malnutrition in PAD patients  

(Each item represents a key heart‑disease–related concept or outcome referenced in the provided clinical statements and guideline citations.)

Page 74 Extracted Terms:
- Peripheral artery disease (PAD)  
- Atherosclerosis  
- Atherosclerotic cardiovascular disease (ASCVD)  
- Coronary artery disease (CAD)  
- Myocardial infarction (MI)  
- Acute coronary syndrome (ACS)  
- Stroke  
- Transient ischemic attack (TIA)  
- Venous thromboembolism (VTE)  
- Atrial fibrillation (AF)  
- Vascular morbidity  
- Mortality  
- Ankle‑brachial index (ABI)  
- Endovascular femoropopliteal intervention  
- Paclitaxel‑eluting stent  
- Rivaroxaban  
- Aspirin  
- Clopidogrel  
- Ticagrelor  
- Vorapaxar  
- Antiplatelet therapy  
- Antithrombotic therapy  
- Anticoagulation therapy  
- Revascularization  
- Bypass surgery  
- Statins (incl. high‑intensity statin therapy)  
- Lipid‑lowering therapy  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- High‑density lipoprotein cholesterol (HDL‑C)  
- PCSK9 inhibitors  
- Evolocumab  
- Alirocumab  
- Lipoprotein(a) (Lp(a))  
- Polyvascular disease  
- Peripheral arterial occlusive disease  
- Symptomatic PAD  
- Asymptomatic PAD  
- Major adverse limb events (MALE)  
- Long‑term survival  
- Clinical guidelines (e.g., ACC/AHA, AHA/ACC/ACE)

Page 75 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Critical Limb Ischemia  
- Statin Therapy  
- High‑Intensity Statin Therapy  
- Antihypertensive Therapy  
- Intensive Blood‑Pressure Control  
- Nebivolol  
- Hydrochlorothiazide  
- β‑Blockers  
- Angiotensin‑Converting Enzyme (ACE) Inhibitors  
- Angiotensin Receptor Blockers (ARBs)  
- Renin–Angiotensin–Aldosterone System (RAAS) Drugs  
- Telmisartan  
- Ramipril  
- Lipoprotein (LDL) Cholesterol  
- Ankle‑Brachial Index  
- Cardiovascular Events  
- Amputation‑Free Survival  
- Mortality  
- Smoking Cessation  
- Varenicline (Nicotine Replacement)  
- Bupropion (Nicotinic Antagonist)  
- Electronic Cigarettes / Vaping  
- Water‑Pipe (Hookah) Smoking  
- Secondhand Smoke Exposure  
- Cardiovascular Disease  
- Atherosclerotic Disease  
- Coronary Artery Disease  
- Hypertension  
- Hyperlipidemia  
- Lifestyle Management (Diet, Exercise)  
- Vascular Operations  
- HOPE Study (Heart Outcomes Prevention Evaluation)  
- EUCLID Trial (Peripheral Artery Disease)

Page 76 Extracted Terms:
**Key heart‑disease terms extracted from the text**

1. Peripheral Artery Disease  
2. Cardiovascular outcomes  
3. Coronary artery disease  
4. Acute coronary syndrome  
5. Myocardial infarction  
6. Heart failure  
7. Atherosclerotic cardiovascular disease  
8. Sodium‑glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, canagliflozin)  
9. Glucagon‑like peptide‑1 (GLP‑1) receptor agonists (liraglutide, semaglutide, exenatide, lixisenatide, tirzepatide)  
10. Diabetes management  
11. Glycemic control  
12. HbA1c variability  
13. Lower‑extremity amputations  
14. Diabetic foot ulcers  
15. Smoking cessation  
16. Electronic cigarettes  
17. Nicotine‑replacement therapy  
18. Influenza vaccination  
19. Dietary sodium reduction  
20. DASH diet (Dietary Approaches to Stop Hypertension)  
21. Mediterranean diet  
22. Hypertension  
23. Endothelial dysfunction  
24. Atherosclerosis  
25. Cardiometabolic health  
26. Cardiovascular ageing  
27. Coronary interventions (percutaneous coronary intervention)  
28. Microvascular complications  
29. Peripheral arterial disease severity  

These terms capture the core clinical concepts, therapies, and preventative strategies discussed in the provided guideline excerpts.

Page 77 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Intermittent Claudication  
- Myocardial Infarction  
- Atherosclerotic Cardiovascular Disease  
- Endovascular Revascularization  
- Restenosis (stent restenosis)  
- Chronic Heart Failure  
- Milrinone (oral)  
- Cilostazol  
- Pentoxifylline  
- Clopidogrel  
- Ticagrelor  
- Rivaroxaban  
- Homocysteine‑lowering therapy (folic acid & B‑vitamins)  
- Vitamin D supplementation (serum 25‑hydroxyvitamin D)  
- Chelation therapy (EDTA‑based, EDTA‑chelating agents)  
- Mediter­rainian dietary pattern (high‑score Mediterranean diet)  
- COVID‑19 cardiovascular comorbidities / outcomes  
- Femoropopliteal lesions  
- Endothelial dysfunction (implied by PAD and atherosclerosis)

Page 78 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Peripheral Arterial Disease  
- Intermittent Claudication  
- Exercise Therapy (supervised)  
- Exercise Therapy (home‑based)  
- Supervised Exercise Training  
- Home‑Based Walking Exercise  
- Walking Exercise Therapy  
- Endovascular Revascularization  
- Percutaneous Transluminal Angioplasty  
- Revascularization (vascular)  
- Vascular Function  
- Vascular Guidelines  
- Endovascular Treatment  
- Angioplasty  
- Claudication  
- Cardiovascular Disease  
- Heart Disease  
- Peripheral Vascular Disease (PVD)

Page 79 Extracted Terms:
Peripheral artery disease (PAD)  
Intermittent claudication  
Endovascular revascularisation  
Conservative management  
Resistance training  
Treadmill exercise training  
Supervised exercise therapy (SET)  
Upper‑limb aerobic exercise  
Lower‑limb aerobic exercise  
Walking distance  
Endothelial function  
Aortic endografting  
Large sheath access  
Lithotripsy for calcified iliacs  
Iliac artery recanalization  
Chronic occlusion  
Aorto‑iliac arterial intervention  
Transcatheter aortic valve replacement (TAVR)  
Femoral access vs non‑femoral access  
Transcarotid access  
Subclavian/axillary access  
Catheter‑based limb angioplasty  
Bypass graft  
Limb‑threatening ischemia  
Acute limb ischemia  
Embolisation  
Complications of percutaneous transluminal angioplasty  
Natural history of arteriosclerosis  
Risk factors for claudication  
Atherosclerosis of lower extremities  
Disease progression  
Cardiovascular events  
Guideline‑recommended therapy  
American Heart Association (AHA)  
American College of Cardiology (ACC)  
Society for Cardiovascular Angiography and Interventions (SCAI)  
Society of Interventional Radiology (SIR)  
Society of Vascular Medicine (SVM)

Page 80 Extracted Terms:
Peripheral artery disease  
Intermittent claudication  
Revascularization  
Endovascular revascularization  
Angioplasty  
Percutaneous transluminal angioplasty (PTA)  
Stenting  
Atherectomy  
Bypass surgery  
Lower extremity bypass  
Common femoral artery disease  
Femoropopliteal disease  
Aortoiliac occlusive disease  
Supervised exercise therapy  
Exercise training  
Endarterectomy  
Thromboendarterectomy  
Restenosis  
Chronic limb‑threatening ischemia  
Surgical versus endovascular comparison  
Invasive versus non‑invasive treatment strategy  
Clinical effectiveness  
Randomized controlled trial  
Meta‑analysis  
Clinical guideline  
SCAI device‑selection guideline  
SVS Vascular Quality Initiative  
SIR data registry  
Reintervention outcomes  
30‑day unplanned readmission  
Quality of life outcomes  
Symptomatic peripheral artery disease  
Peri‑operative outcomes  
Multicenter study  
Prospective randomized trial  
Open repair versus endovascular repair  
Routine versus selective stenting  
Bifurcation lesion management  
Procoagulant and hypofibrinolytic state  
Patient‑reported outcomes  
Health‑related quality of life  
Endovascular versus surgical management  
Percutaneous transluminal balloon angioplasty  
Endovascular treatment of common femoral artery stenosis  
Endovascular intervention in symptomatic peripheral arterial disease  
Clinical registry outcomes.

Page 81 Extracted Terms:
- Peripheral Artery Disease  
- Critical Limb Ischemia  
- Intermittent Claudication  
- Endovascular Revascularization  
- Femoro‑Popliteal Angioplasty  
- Femoro‑Popliteal Bypass  
- Stent Placement (Common Femoral, Iliac)  
- Endarterectomy (Common Femoral)  
- Hybrid Surgery (Endovascular + Open)  
- Aorto‑Iliac Disease  
- Vascular Surgery (Open Reconstruction)  
- Cardiovascular Disease  
- Cardiovascular Interventions  
- ACC/AHA Appropriate Use Criteria  
- SCAI Guidelines (Device Selection, Endovascular Specialists)  
- Percutaneous Translational Angioplasty  
- Bio‑absorbable Stent Implantation  
- Vein Graft vs. PTFE Graft (Bypass)  
- Multidisciplinary/Team‑Based Care for Chronic Limb‑Threatening Ischemia  
- Perioperative Cardiovascular Evaluation and Management (ACC/AHA 2014)  
- Vascular Quality Initiative (Clinical Outcomes Database)  
- Angiographic Criteria/Pressure Measurements (Hemodynamic Significance)  
- Long‑Term Patency / Long‑Term Success (Angioplasty/Bypass)  
- Surgical vs. Endovascular Therapy for Chronic Limb‑Threatening Ischemia  
- Wound Healing / Amputation‑Free Survival in CLTI  
- Clinical Practice Guidelines (AHA/ACC, SCAI, SVS, etc.)

Page 82 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI) / Critical Limb Ischemia (CLI)  
- Femoropopliteal Bypass  
- Iliac Artery Stenting  
- Femoral Endarterectomy  
- Hybrid Procedure (combination of open and endovascular)  
- Endovascular Intervention (angioplasty, stenting)  
- Angiosome‑Targeted Revascularization  
- Composite Vein Bypass  
- Saphenous Vein Graft (great, small, or femoral)  
- Polytetrafluoroethylene (PTFE) Prosthetic Graft  
- Autologous Vein Graft  
- Limb Salvage  
- Graft Patency  
- Antithrombotic Therapy  
- Bypass versus Angioplasty (BASIL) Trial  
- Open Infrainguinal Bypass  
- Aortoiliac Occlusive Disease  
- Aortoiliac‑Femoral Occlusive Disease  
- Infrapopliteal Intervention  
- Infrapopliteal Bypass  
- Vascular Quality Initiative (VQI) Database  
- Clinical Outcomes & Registry Data (e.g., CRITISCH, SPINACH, BASIL, BASIL‑2)  
- Graft Failure and Technical Factors  
- Spliced Arm Vein Graft  
- Pre‑cuffed PTFE vs. Vein‑cuffed PTFE Graft  
- Surgical Reconstruction vs. Endovascular Placement  
- Perioperative Outcomes  
- Meta‑analysis of PAD interventions  
- Graft Type Comparison (prosthetic vs. autogenous)  
- Infragenicular Arterial Bypass  
- Endovascular Era Outcomes  
- Critical Limb Ischemia Management Guidelines  
- Composite vs. Conventional Vein Conduit  
- Direct vs. Indirect Angiosomal Revascularization  
- Angioplasty‑First vs. Bypass‑First Strategy  

*(All terms directly relate to cardiovascular (heart and peripheral vascular) disease and its interventional management.)*

Page 83 Extracted Terms:
- Peripheral arterial disease (PAD)  
- Critical limb ischemia (CLI/CLTI)  
- Lower‑extremity ischemia  
- Vascular disease  
- Angiosome  
- PTFE bypass (peripheral bypass)  
- Endovascular therapy  
- Collateral vessels  
- Hemodynamic effects  
- Prostanoids (pharmacologic agents in arterial disease)  
- Intermittent pneumatic compression  
- Sequential pneumatic compression  
- Revascularization  
- Angiology (clinical specialty)  
- Vascular surgery (procedural specialty)

Page 84 Extracted Terms:
- Peripheral arterial disease  
- Chronic limb‑threatening ischemia (CLTI)  
- Critical limb ischemia (CLI)  
- Lower‑extremity amputation  
- Wound, Ischemia, Foot Infection (WIfI) classification  
- Vascular surgery / endovascular intervention  
- Revascularization  
- Deep venous arterialization  
- Cardiovascular events (e.g., myocardial infarction, stroke)  
- Smoking cessation pharmacotherapies  
- American Heart Association policy statements  
- National Cardiovascular Data Registry (NCDR)  
- Society of Thoracic Surgeons (STS) national database  
- Global vascular guidelines on chronic limb‑threatening ischemia  
- Health‑related quality of life after vascular procedures  
- Multidisciplinary vascular care teams  
- Non‑reconstructable peripheral arterial disease  
- Ischemic foot ulcer in diabetic patients  

*(All terms extracted directly from the provided guideline references.)*

Page 85 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

1. Acute limb ischemia  
2. Peripheral artery disease  
3. Peripheral atherosclerotic vascular disease  
4. Lower extremity ischemia  
5. Acute lower extremity ischemia  
6. Arterial thrombosis  
7. Arterial embolism  
8. Arterial thromboembolism  
9. Vascular occlusion  
10. Thrombolysis  
11. Catheter‑directed thrombolysis  
12. Ultrasound‑accelerated thrombolysis  
13. Percutaneous mechanical thrombectomy  
14. Endovascular revascularization  
15. Surgical revascularization  
16. Bypass graft  
17. Vascular graft  
18. Lower extremity bypass  
19. Vascular complications of cancer treatments (vascular‑related heart disease)

Page 86 Extracted Terms:
- Peripheral Arterial Disease (PAD)  
- Acute Limb Ischemia (ALI)  
- Acute Lower‑Limb Ischemia  
- Lower‑Extremity Thrombosis  
- Thrombolysis (intra‑arterial, catheter‑directed)  
- Heparin‑Induced Thrombocytopenia (HIT)  
- Anticoagulation Therapy  
- Antiplatelet Therapy  
- Rivaroxaban  
- Vorapaxar  
- Aspirin  
- Statin Therapy (e.g., simvastatin)  
- Hypercoagulable Syndromes  
- Antiphospholipid Antibody Syndrome  
- Atrial Fibrillation (non‑valvular)  
- Cardiogenic Limb Emboli  
- Aortic Dissection (type B)  
- Aortic Aneurysm (infra‑inguinal, popliteal)  
- Popliteal Entrapment/ Aneurysm  
- COVID‑19–Associated Thrombosis  
- Carotid Artery Disease  
- Ischemia (general)  
- Compartment Syndrome (acute extremity)  
- Fasciotomy (therapeutic)  
- Quality of Life in Peripheral Vascular Disease  
- Major Cardiovascular Events (stroke, myocardial infarction, heart failure)

Page 87 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower extremity ischemia  
- Critical limb ischemia  
- Limb‑threatening ischemia  
- Revascularization (endovascular, surgical)  
- Bypass graft failure  
- Infrainguinal bypass graft  
- Prosthetic bypass graft  
- Dual‑antiplatelet therapy  
- Antiplatelet agents (aspirin, clopidogrel, ticagrelor)  
- Antithrombotic agents (rivaroxaban, rivaroxaban + aspirin)  
- Anticoagulation therapy  
- Statin therapy  
- LDL‑cholesterol lowering  
- PCSK9 inhibition (evolocumab)  
- Glycemic control  
- Diabetes mellitus type 2  
- Hemoglobin A1c  
- Foot ulcer  
- Lower‑extremity amputation  
- Patency (vascular graft patency)  
- Cardiovascular events (myocardial infarction, stroke)  
- Cardiovascular risk  
- Cardiovascular outcomes  
- Vascular imaging (duplex ultrasound, duplex surveillance)  
- Ultrasound surveillance  
- Endovascular injury  
- Neo‑intimal hyperplasia  
- Telehealth for PAD management  
- Digital health monitoring  
- Electronic consults  
- Multidisciplinary vascular team  
- Patient‑reported outcomes  
- Depression (co‑morbid psychological factors)  
- American Heart Association guidelines  
- Atherosclerosis  
- Atherosclerotic cardiovascular disease  
- Vascular surgery follow‑up  
- Peripheral vascular disease  
- Chronic limb‑threatening ischemia guidelines  
- LDL‑lowering therapy guidelines  
- Antiplatelet therapy guidelines  
- Glycemic control guidelines  
- Lipid‑lowering therapy guidelines.

Page 88 Extracted Terms:
- Peripheral Artery Disease  
- Lower Extremity Peripheral Artery Disease  
- Heart  
- Heart & Vascular Institute  
- Vascular Center  
- Vascular Medicine  
- Vascular Surgery  
- Anticoagulation Forum  
- ACC/AHA Guidelines (Cardiology)  
- Circulation (journal)

Page 89 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Peripheral Artery Disease  
- Cardiovascular  
- Heart  
- Cardiac  
- Vascular  
- AHA/ACC (American Heart Association / American College of Cardiology)  
- Heart Center  
- Cardiovascular Medicine  
- Cardiovascular Systems  
- Cardiology (implied from “Cardiovascular”)  
- Heart Center Director of Education  
- Cardiovascular Medicine  
- New Cardiovascular Horizons  
- Cardiovascular (implied in multiple references)  

**Relevant industry / technology terms (often linked to heart disease management)**  

- Abbott  
- Medtronic  
- Boston Scientific  
- Cordis / Cardinal Health  
- Amgen  
- Janssen Pharmaceuticals  
- Nuvasive  
- Penumbra  
- Shockwave Medical  
- W.L. Gore (Surgical/medical devices)  
- Silk Road Medical  
- Cardiovascular Systems (company name)  
- Cardiac (brand of products implied)  

These items capture the primary cardiovascular or heart‑related concepts, roles, and vendor references appearing in the provided guideline excerpt.

Page 90 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular  
- Cardiology  
- Cardiac Catheterization Laboratory  
- Vascular Surgery  
- Vascular Medicine  
- Arteriopathy Clinic  
- Heart Hospital  

Page 91 Extracted Terms:
- Peripheral Artery Disease  
- Acute limb ischemia  
- Women’s Heart Clinic  
- Comprehensive Cardiology Clinic  
- Cardiology  
- Vascular Surgery  
- Vascular Intervention  
- Interventional Radiology  
- Endovascular  
- Angiodynamics  
- Vascular Surgery Fellowship  
- Vascular Surgery Residency

Page 92 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular  
- Vascular  
- Heart  
- Cardiovascular Medicine  
- Cardiovascular Interventional  
- Cardiovascular Interventional Fellows  
- Heart and Vascular Institute  
- Cardiovascular device manufacturers  
  - Abbott  
  - Boston Scientific  
  - Medtronic  
  - Philips  
  - Terumo  
  - Inari Medical  
  - Trireme Medical

Page 93 Extracted Terms:
- ACS (Acute Coronary Syndrome)  
- Peripheral Artery Disease  
- Heart & Vascular Center  
- Interventional and Cardiovascular Programs  
- Cardiovascular  
- Cardiology  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)

Page 94 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular  
- Chest Pain Centers  
- Invasive Cardiology  
- Myocardial  
- Ischemia  
- Vascular  
- Endo‑tronic (endovascular)  
- MyoKardia (myocardial therapy)  
- Ischemix (ischemic vascular therapy)

Page 95 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Peripheral Artery Disease (PAD)  
- Lower‑Extremity Peripheral Artery Disease  
- Spontaneous Coronary Artery Dissection (SCAD)  
- Cardiovascular  
- Cardiovascular Disease  
- Cardiac / Heart  
- Vascular  
- Vascular Disease  
- Endovascular  
- Cardiovascular Angiography  
- Cardiovascular Interventions  
- American College of Cardiology (ACC) – major cardiovascular body  
- American Heart Association (AHA) – major cardiovascular body  
- National Heart, Lung, and Blood Institute (NHLBI) – key cardiovascular research institute  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society for Vascular Medicine (SVM)  
- Society for Vascular Surgery (SVS)  
- Society for Interventional Radiology (SIR)  
- Academy of Cardiovascular & Pulmonary Rehabilitation (AACVPR)  

These terms capture the primary disease concepts, related specialties, and major professional organizations discussed in the guideline excerpt.

Page 96 Extracted Terms:
- Peripheral Artery Disease  
- PAD  
- ACC/AHA PAD Guideline  
- AHA (American Heart Association)  
- Heartflow  
- Cardiovascular Research Group  
- Thrombosis Research Institute  
- Heart disease  
- Cardiovascular  
- Heart  
- Vascular  



Page 97 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- ACC/AHA PAD Guideline  
- American Heart Association (AHA)  
- American Society of Echocardiography (ASE)  
- Society for Vascular Surgery (SVS)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Cardio‑vascular  
- Heartflow  
- Hurst’s The Heart Online  
- Circulation (peer‑reviewed cardiovascular journal)

Page 98 Extracted Terms:
- Peripheral Artery Disease (PAD)
- Cardiovascular
- Vascular
- Heart disease
- Cardiovascular disease
- Cardiovascular angiography
- Cardiovascular interventions
- Cardiovascular rehabilitation
- Cardiovascular & pulmonary rehabilitation
- Echocardiography
- Cardiovascular imaging
- American College of Cardiology (ACC)
- American Heart Association (AHA)
- National Heart, Lung, and Blood Institute (NHLBI)
- Society for Vascular Medicine (SVM)
- Society for Vascular Nursing (SVN)
- Society for Vascular Surgery (SVS)
- Society for Cardiovascular Angiography & Interventions (SCAI)
- American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)
- American Association of Black Cardiologists (ABC)
- Association of Podiatric Medical Association (APMA)
- National Institutes of Health (NIH)
- Patient-Centered Outcomes Research Institute (PCORI)
- Duke Clinical Research Institute (DCRI)
- Medtronic (device manufacturer relevant to cardiovascular therapy)

